BioLine RX Ltd
biolinerx.comWhat Do They Do?
Develops treatments for oncology and rare diseases, including motixafortide for stem-cell mobilization and solid tumors and an oral candidate for glioblastoma and other cancers.
20-F for FY2025, filed Mar 23, 2026
Who Are Their Customers?
Ayrmid and Gloria hold motixafortide rights under licensing deals; during direct U.S. sales, BioLineRx sold mainly to wholesale distributors.
20-F for FY2025, filed Mar 23, 2026
Do Revenues Turn Into Profits?
No. It lost $2M in .
20-F for FY2025, filed Mar 23, 2026
How Are They Changing?
Partner-led commercialization
The older report planned independent U.S. commercialization of motixafortide; the latest says it licensed rights to partners and ended its U.S. commercial operations, shifting its focus to development.
20-F for FY2022, filed Mar 22, 2023 20-F for FY2025, filed Mar 23, 2026We are a pre-commercial-stage biopharmaceutical company focused on oncology. Our current development and commercialization pipeline…View ↗
In October 2023, we out-licensed the rights to motixafortide for all indications in substantially all of Asia to Gloria, and in November…View ↗
Broader pipeline
The older report described an oncology-focused pipeline; the latest also pursues rare diseases and adds a collaboration to develop an oral cancer candidate.
20-F for FY2022, filed Mar 22, 2023 20-F for FY2025, filed Mar 23, 2026We are a pre-commercial-stage biopharmaceutical company focused on oncology. Our current development and commercialization pipeline…View ↗
Who Do They Compete With?
Competes with Novocure, Sanofi Genzyme, Plus Therapeutics, Telix, TVAX Biomedical, Imvax, GSK, AstraZeneca, Vigeo Therapeutics, Biohaven, Polaris, Kintara Therapeutics, Bayer, Oniria Therapeutics, General Oncology, Quercis Pharma, Renovion, Exicure, TCM Biotech, and Ipsen
20-F for FY2025, filed Mar 23, 2026In the field of glioblastoma (GBM), therapeutic candidates compete indirectly with a small number of established modalities. In newly…View ↗
Loading...
